Oculis Holding AG (FRA:CR5) Other Net Income (Loss) : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Other Net Income (Loss)?

Oculis Holding AG's Other Net Income (Loss) for the three months ended in Mar. 2024 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Oculis Holding AG's annual Other Net Income (Loss) increased from Dec. 2021 (€-0.00 Mil) to Dec. 2022 (€-0.00 Mil) and increased from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).

Oculis Holding AG Other Net Income (Loss) Historical Data

The historical data trend for Oculis Holding AG's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Other Net Income (Loss) Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial							-	-	-	-	-

Oculis Holding AG Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Oculis Holding AG Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (FRA:CR5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (FRA:CR5) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

OCS:USA CR5:Germany

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Oculis Holding AG (FRA:CR5) Headlines

No Headlines